Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WATCHMAN FLX vs NOAC in Non-Valvular Atrial Fibrillation
NCT04394546Active, not recruiting
- Sponsor
- Boston Scientific Corporation
- Start
- Oct 2020
- Primary completion
- Dec 2027
- Countries
- 16
01
Overview
Randomised, open-label trial in Atrial fibrillation (AFib) (2 arms), sponsored by Boston Scientific Corporation. Primary endpoints: Occurrence of stroke, cardiovascular death, and systemic embolism at 36 months, Occurrence of non-procedural bleeding (ISTH major bleeding and clinically relevant non-major bleeding) at 36 months and 1 more. Started Oct 2020; status: active, not recruiting.
02
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04394546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04394546.